Drug Trial Radar · NCT03706079
Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma
Last checked: Nov 20, 2026Latest source record: Jun 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
951
Actual
Start
Jan 7, 2019
Primary completion
Oct 26, 2021
Study completion May 18, 2022
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Amgen
- First posted
- Oct 15, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 13 years, up to 81 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Subjects who completed either D5180C00007 or D5180C00009 will be offered the opportunity to consent for the Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. The study consists of a treatment phase, followed by a follow-up phase where subjects will not receive IP. The length of the follow up phase is determined by which study the subject had previously completed.
Conditions
- Asthma
Interventions
TezepelumabBiological
Tezepelumab subcutaneous injection
PlaceboOther
Placebo subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Exposure Adjusted Incidence Rates of AEs/SAEsTime frame: Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.
- Total Time at RiskTime frame: Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.
Locations
180 sites in 18 countries. Site status is shown where the registry gives one.
Research Site
Dothan, Alabama
Research Site
Gilbert, Arizona
Research Site
Bakersfield, California
Research Site
Huntington Beach, California
Research Site
Long Beach, California
Research Site
Los Angeles, California
Research Site
Newport Beach, California
Research Site
Northridge, California
Research Site
Palm Desert, California
Research Site
Rolling Hills Estates, California
Research Site
Walnut Creek, California
Research Site
Westminster, California
Research Site
New Haven, Connecticut
Research Site
Kissimmee, Florida
Research Site
Kissimmee, Florida
Research Site
Port Charlotte, Florida
Research Site
Sarasota, Florida
Research Site
Tampa, Florida
Research Site
Winter Park, Florida
Research Site
Boise, Idaho
Research Site
Zachary, Louisiana
Research Site
White Marsh, Maryland
Research Site
Boston, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
St Louis, Missouri
Research Site
Lincoln, Nebraska
Research Site
Las Vegas, Nevada
Research Site
Northfield, New Jersey
Research Site
Brooklyn, New York
Research Site
The Bronx, New York
Research Site
The Bronx, New York
Research Site
Charlotte, North Carolina
Research Site
Durham, North Carolina
Research Site
Winston-Salem, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Cincinnati, Ohio
Research Site
Edmond, Oklahoma
Research Site
Oklahoma City, Oklahoma
Research Site
Medford, Oregon
Research Site
Philadelphia, Pennsylvania
Showing 40 of 180 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.